The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture. More: UCB, Amgen’s Evenity under review in Europe Source: News
read moreShire has unveiled plans to split its operations into two separate entities – a neuroscience division and rare diseases one, and will later decide whether they should be listed independently. More: Shire to split operations in two Source: News
read moreShares in Axovant Sciences Ltd sank almost 50 percent after investors shrank back on new of the failure of lead drug intepirdine in a mid-stage study in patients with a particular kind of dementia. More: Axovant shares plummet on dementia
read moreAustrian vaccine company Themis has secured a €10 million series C led by new investor Global Health Investment Fund, which was formed by J.P. Morgan and the Bill & Melinda Gates Foundation. More: Themis nabs €10M series C for chikungunya,
read more© 1994 - 2026 B.M. Pharmaceuticals